The original Medical Research Council (MRC) dyspnoea scale was developed by the British MRC in the 1950s, and it was first formally published in 1961 in a study on chronic bronchitis.1 It was designed ...

The group assignment of chronic obstructive pulmonary disease (COPD) may differ depending on whether the COPD assessment test (CAT) or modified Medical Research Council dyspnoea scale (mMRC) is used.

The guidelines state the recommended first choice pharmacologic therapy, an alternative choice and other possible treatments for each category: A—‘low risk, less symptoms’; B—‘low risk, more symptoms’ ...

When to begin maintenance therapy for patients with chronic obstructive pulmonary disease (COPD) with either a single drug, or a combination of long-acting bronchodilators, is not always clear. A new ...

Socioeconomic factors, including education and employment status, along with clinical parameters, such as modified Medical Research Council (mMRC) dyspnea scale and Charlson Comorbidity Index (CCI) ...

"Our findings demonstrate that dyspnea, frequent exacerbations, and other aspects of disease severity associate with worse quality of life, particularly its physical component." -- Radmila Choate, PhD ...

PARIS -- Use of targeted lung denervation (TLD) on top of a long-acting bronchodilator in moderate-to-severe chronic obstructive pulmonary disease (COPD) cut respiratory-related events by more than ...

Poor sleep quality in PAH patients is linked to increased dyspnea and reduced exercise capacity, worsening disease burden. Severe dyspnea is a significant predictor of poor sleep quality, independent ...

Introduction Dyspnoea is an existentially burdensome symptom in patients with advanced and progressive diseases such as cancer, chronic obstructive pulmonary disease (COPD) and advanced heart failure.